Equities research analysts at Aegis assumed coverage on shares of NuVasive Inc. (NASDAQ:NUVA) in a report released on Wednesday. The brokerage set a “buy” rating and a $72.00 price target on the medical device company’s stock. Aegis’ price objective points to a potential upside of 10.04% from the stock’s current price.

NUVA has been the subject of several other reports. Barclays PLC boosted their target price on NuVasive from $71.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, October 10th. Jefferies Group reissued a “buy” rating on shares of NuVasive in a report on Wednesday, August 3rd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $70.00 target price on shares of NuVasive in a report on Thursday, September 1st. Zacks Investment Research downgraded NuVasive from a “buy” rating to a “hold” rating in a report on Tuesday, October 25th. Finally, TheStreet downgraded NuVasive from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 25th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $66.83.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Shares of NuVasive (NASDAQ:NUVA) opened at 65.43 on Wednesday. NuVasive has a one year low of $36.81 and a one year high of $69.50. The firm has a 50-day moving average price of $62.89 and a 200 day moving average price of $61.83. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of 82.61 and a beta of 0.98.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Tuesday, October 25th. The medical device company reported $0.40 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.40. The business earned $239.60 million during the quarter, compared to analysts’ expectations of $243.49 million. NuVasive had a return on equity of 10.89% and a net margin of 4.06%. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 EPS. Equities analysts forecast that NuVasive will post $1.64 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “NuVasive Inc. (NUVA) Now Covered by Aegis” was first published by Financial Market News and is the propert of of Financial Market News. If you are accessing this story on another domain, it was copied illegally and republished in violation of United States & international copyright law. The legal version of this story can be read at http://www.financial-market-news.com/nuvasive-inc-nuva-now-covered-by-aegis/1210424/.

In other news, EVP Joan Stafslien purchased 5,000 shares of the stock in a transaction that occurred on Monday, October 31st. The shares were acquired at an average price of $59.68 per share, for a total transaction of $298,400.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Patrick Miles purchased 16,967 shares of the stock in a transaction that occurred on Wednesday, November 2nd. The stock was purchased at an average price of $58.97 per share, for a total transaction of $1,000,543.99. The disclosure for this purchase can be found here. 4.70% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in NUVA. ETRADE Capital Management LLC purchased a new stake in NuVasive during the third quarter worth $865,000. Sheets Smith Wealth Management purchased a new stake in NuVasive during the third quarter worth $531,000. Scout Investments Inc. boosted its stake in NuVasive by 92.4% in the third quarter. Scout Investments Inc. now owns 302,595 shares of the medical device company’s stock worth $20,171,000 after buying an additional 145,281 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in NuVasive by 2.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 17,895 shares of the medical device company’s stock worth $1,193,000 after buying an additional 380 shares in the last quarter. Finally, LPL Financial LLC purchased a new stake in NuVasive during the third quarter worth $251,000.

NuVasive Company Profile

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

5 Day Chart for NASDAQ:NUVA

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.